154 related articles for article (PubMed ID: 37717341)
1. F77 antigen is a promising target for adoptive T cell therapy of prostate cancer.
Grover P; Nunez-Cruz S; Leferovich J; Wentz T; Bagchi A; Milone MC; Greene MI
Biochem Biophys Res Commun; 2023 Nov; 680():51-60. PubMed ID: 37717341
[TBL] [Abstract][Full Text] [Related]
2. Fourth-generation chimeric antigen receptor T cells targeting folate receptor alpha antigen expressed on breast cancer cells for adoptive T cell therapy.
Luangwattananun P; Junking M; Sujjitjoon J; Wutti-In Y; Poungvarin N; Thuwajit C; Yenchitsomanus PT
Breast Cancer Res Treat; 2021 Feb; 186(1):25-36. PubMed ID: 33389403
[TBL] [Abstract][Full Text] [Related]
3. Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy.
Ma Q; Gomes EM; Lo AS; Junghans RP
Prostate; 2014 Feb; 74(3):286-96. PubMed ID: 24174378
[TBL] [Abstract][Full Text] [Related]
4. Suppression of human prostate tumor growth by a unique prostate-specific monoclonal antibody F77 targeting a glycolipid marker.
Zhang G; Zhang H; Wang Q; Lal P; Carroll AM; de la Llera-Moya M; Xu X; Greene MI
Proc Natl Acad Sci U S A; 2010 Jan; 107(2):732-7. PubMed ID: 20080743
[TBL] [Abstract][Full Text] [Related]
5. Anti-PSMA CAR-engineered NK-92 Cells: An Off-the-shelf Cell Therapy for Prostate Cancer.
Montagner IM; Penna A; Fracasso G; Carpanese D; Dalla Pietà A; Barbieri V; Zuccolotto G; Rosato A
Cells; 2020 Jun; 9(6):. PubMed ID: 32498368
[TBL] [Abstract][Full Text] [Related]
6. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
Front Immunol; 2021; 12():665970. PubMed ID: 34475869
[TBL] [Abstract][Full Text] [Related]
7. Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM.
Deng Z; Wu Y; Ma W; Zhang S; Zhang YQ
BMC Immunol; 2015 Jan; 16(1):1. PubMed ID: 25636521
[TBL] [Abstract][Full Text] [Related]
8. Construction of a chimeric antigen receptor bearing a nanobody against prostate a specific membrane antigen in prostate cancer.
Hassani M; Hajari Taheri F; Sharifzadeh Z; Arashkia A; Hadjati J; van Weerden WM; Modarressi MH; Abolhassani M
J Cell Biochem; 2019 Jun; 120(6):10787-10795. PubMed ID: 30672018
[TBL] [Abstract][Full Text] [Related]
9. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
[TBL] [Abstract][Full Text] [Related]
10. Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.
Hillerdal V; Essand M
BioDrugs; 2015 Apr; 29(2):75-89. PubMed ID: 25859858
[TBL] [Abstract][Full Text] [Related]
11. Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma.
Shen CJ; Yang YX; Han EQ; Cao N; Wang YF; Wang Y; Zhao YY; Zhao LM; Cui J; Gupta P; Wong AJ; Han SY
J Hematol Oncol; 2013 May; 6():33. PubMed ID: 23656794
[TBL] [Abstract][Full Text] [Related]
12. A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer.
Abate-Daga D; Lagisetty KH; Tran E; Zheng Z; Gattinoni L; Yu Z; Burns WR; Miermont AM; Teper Y; Rudloff U; Restifo NP; Feldman SA; Rosenberg SA; Morgan RA
Hum Gene Ther; 2014 Dec; 25(12):1003-12. PubMed ID: 24694017
[TBL] [Abstract][Full Text] [Related]
13. Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering.
Han X; Cinay GE; Zhao Y; Guo Y; Zhang X; Wang P
Mol Ther; 2017 Nov; 25(11):2466-2476. PubMed ID: 28784559
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Optimization of a CD20-specific Chimeric Antigen Receptor Vector and Culture Conditions.
Lee SY; Olsen P; Lee DH; Kenoyer AL; Budde LE; O'Steen S; Green DJ; Heimfeld S; Jensen MC; Riddell SR; Press OW; Till BG
J Immunother; 2018 Jan; 41(1):19-31. PubMed ID: 29176334
[TBL] [Abstract][Full Text] [Related]
15. Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice.
Hillerdal V; Ramachandran M; Leja J; Essand M
BMC Cancer; 2014 Jan; 14():30. PubMed ID: 24438073
[TBL] [Abstract][Full Text] [Related]
16. Design and Assessment of Novel Anti-CD30 Chimeric Antigen Receptors with Human Antigen-Recognition Domains.
Choi S; Pegues MA; Lam N; Geldres C; Vanasse D; Kochenderfer JN
Hum Gene Ther; 2021 Jul; 32(13-14):730-743. PubMed ID: 33287637
[TBL] [Abstract][Full Text] [Related]
17. Carbohydrate sequence of the prostate cancer-associated antigen F77 assigned by a mucin O-glycome designer array.
Gao C; Liu Y; Zhang H; Zhang Y; Fukuda MN; Palma AS; Kozak RP; Childs RA; Nonaka M; Li Z; Siegel DL; Hanfland P; Peehl DM; Chai W; Greene MI; Feizi T
J Biol Chem; 2014 Jun; 289(23):16462-77. PubMed ID: 24753245
[TBL] [Abstract][Full Text] [Related]
18. Chimeric cytokine receptor enhancing PSMA-CAR-T cell-mediated prostate cancer regression.
Weimin S; Abula A; Qianghong D; Wenguang W
Cancer Biol Ther; 2020 Jun; 21(6):570-580. PubMed ID: 32208880
[No Abstract] [Full Text] [Related]
19. Secretion of 4-1BB Ligand Crosslinked to PD-1 Checkpoint Inhibitor Potentiates Chimeric Antigen Receptor T Cell Solid Tumor Efficacy.
Dunn ZS; Qu Y; MacMullan M; Chen X; Cinay G; Wang P
Hum Gene Ther; 2023 Nov; 34(21-22):1145-1161. PubMed ID: 36851890
[TBL] [Abstract][Full Text] [Related]
20. Engineered Jurkat Cells for Targeting Prostate-Specific Membrane Antigen on Prostate Cancer Cells by Nanobody-Based Chimeric Antigen Receptor.
Hassani M; Hajari Taheri F; Sharifzadeh Z; Arashkia A; Hadjati J; van Weerden WM; Abdoli S; Modarressi MH; Abolhassani M
Iran Biomed J; 2020 Mar; 24(2):81-8. PubMed ID: 31677604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
